Peptides DB
Research-centric peptide and protocol reference hub
Study 50 of 50VIP (Vasoactive Intestinal Polypeptide) literatureJournal of ethnopharmacology · Meta-analysis2026

Exploring the therapeutic role of Chinses herbal medicine in the recurrence rate of uterine fibroids after conservative surgery: a systematic review and meta-analysis.

CHM may reduce the recurrence rate of uterine fibroids after surgery, but these findings are preliminary and need further validation.

Read at Journal of ethnopharmacologyAdd to compare

Where it sits

this study against the rest of the vip (vasoactive intestinal polypeptide) corpus
10
Preclinical
32
Observational
1
Open-label
2
Randomised
5
Reviews · this one

Summary and findings

This study conducted a meta-analysis of randomized controlled trials evaluating the efficacy and safety of Chinese herbal medicine (CHM) in reducing the postoperative recurrence rate of uterine fibroids. The analysis included 16 trials with varying comparisons to blank controls, conventional western medicine, and combined treatments. The findings suggest a reduction in recurrence rates, but further validation through higher-quality studies is necessary.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
OR = 0.22; 95% CI = 0.14-0.34; I2 = 0%; p < 0.00001 for CHM vs blank controls, n = 588n=16272026

Abstract

The authors’ words, as Journal of ethnopharmacology supplied them

<h4>Ethnopharmacological relevance</h4>Since surgery can only remove lesions of a larger size visible to the naked eye, the recurrence rate of uterine fibroids after surgery is high. In recent years, numerous scholars have found that traditional Chinese medicine (TCM) treatment is effective in reducing the recurrence rate of postoperative fibroids, as well as improving the clinical treatment rate, regulating serum hormone levels, reducing plasma viscosity, and promoting the restoration of uterine volume following surgery. Several randomized controlled trials have been undertaken on the prevention and treatment of postoperative recurrence of uterine fibroids using patented Chinese medicines and self-proposed formulations, such as Guizhi Fuling Pill, Xiaozheng decoction, Xiangleng pill, Zhengjia decoction, Xiaoliu decoction, Guizhi Jiliu pill, Huoxue Huayu formula, Huoxue Xiaozheng decoction, Shugan Sanjie decoction, Gongliuxiao capsule, Hongjin Xiaojie concentrated pill, and Jiawei Guizhi Fuling decoction. However, no study has systematically evaluated Chinese herbal medicine (CHM) in reducing the recurrence rate of uterine fibroids after surgery.<h4>Aim of the study</h4>This study aimed to conduct a meta-analysis of randomized controlled trials of CHM for the prevention of postoperative recurrence of uterine fibroids, evaluating its efficacy and safety.<h4>Materials and methods</h4>A comprehensive search was conducted on PubMed, Cochrane, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), VIP Information Database (VIP), WanFang Database, and China Biomedical Database (CBM) to identify randomized controlled clinical studies conducted up to March 2025 that examined the efficacy of CHM in treating patients with postoperative uterine fibroids. Two institutes were independently under-selected, and data were extracted and quality assessed using the Cochrane Risk of Bias 2.0 tool. Meta-analyses were performed using Review Manager software 5.4, and forest plots were generated. The quality of evidence was assessed using GRADEpro 3.2.2. This study was registered in PROSPERO (CRD420251000288).<h4>Results</h4>16 trials were included in this study, and the postoperative recurrence rate after treatment was mainly analyzed. CHM treatment reduces postoperative recurrence rates in patients with uterine fibroids compared to the blank (6 trials, n = 588; OR (odds ratio) = 0.22; 95 % CI (95 % confidence intervals) = 0.14-0.34; I<sup>2</sup> = 0 %, p < 0.00001), conventional western medicine (CWM) (1 trial, n = 80; OR = 0.30; 95 % CI = 0.09-0.93, p = 0.04), and combined CHM with CWM (9 trials, n = 959; OR = 0.29; 95 % CI = 0.19-0.46; I<sup>2</sup> = 0 %, p < 0.00001). In addition, CHM is also effective in improving clinical efficiency, restoring serum sex hormone levels, lowering plasma viscosity, and reducing uterine volume. CHM is generally considered safe, with a low incidence of adverse reactions.<h4>Conclusion</h4>CHM is effective in avoiding recurrence of uterine fibroids after surgery, excelling in terms of overall effectiveness, restoring female hormone levels, improving hemorheological indices, and promoting uterine recovery and safety. However, these findings are preliminary and still need to be validated by higher-quality studies.

Background

This paper addresses the recurrence of uterine fibroids after conservative surgery, a known issue due to the limitations of surgical intervention. Previous studies have suggested that traditional Chinese medicine (TCM) may be effective in reducing recurrence rates and improving various clinical outcomes. This systematic review and meta-analysis aims to evaluate the efficacy and safety of CHM in this context, filling a gap in the existing literature.

Methods

The study conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) on CHM for postoperative uterine fibroids. A comprehensive search was performed across multiple databases up to March 2025. Sixteen trials were included, with various comparisons made regarding recurrence rates, clinical efficiency, and safety outcomes.

Results

The primary endpoint showed that CHM treatment significantly reduces postoperative recurrence rates compared to blank controls (OR = 0.22; 95% CI = 0.14-0.34; I2 = 0%; p < 0.00001, n = 588). Additional comparisons indicated similar reductions in recurrence rates against conventional western medicine and combined therapies. The study also noted improvements in clinical efficiency and safety.

Interpretation

The results align with prior literature suggesting that CHM may have a role in managing postoperative outcomes for uterine fibroids. While the effect sizes are statistically significant, the clinical significance remains to be fully established. Limitations such as the quality of included studies and potential biases may affect the reliability of these findings.

Key findings

  • CHM treatment reduces postoperative recurrence rates compared to blank controls (OR = 0.22; 95% CI = 0.14-0.34; I2 = 0%; p < 0.00001, n = 588).
  • CHM treatment reduces postoperative recurrence rates compared to conventional western medicine (OR = 0.30; 95% CI = 0.09-0.93; p = 0.04, n = 80).
  • CHM treatment reduces postoperative recurrence rates when combined with conventional western medicine (OR = 0.29; 95% CI = 0.19-0.46; I2 = 0%; p < 0.00001, n = 959).
  • CHM is effective in improving clinical efficiency, restoring serum sex hormone levels, lowering plasma viscosity, and reducing uterine volume.
  • CHM is generally considered safe, with a low incidence of adverse reactions.

Limitations

  • small n in some trials
  • industry funding not reported
  • heterogeneity in treatment protocols
  • short follow-up duration
  • quality of included studies varies

Elsewhere in the VIP (Vasoactive Intestinal Polypeptide) corpus

CSingle-nucleus RNA-seq atlas of 5xFAD mouse brain maps cell-type-specific transcriptional disruption and preferential rolipram rescue in VIP interneuronsbiorxiv-preprint · 2026 · 289 candidate genes were lower in 5xFAD VIP interneurons, padj = 1.5x10^-14.AnimalBPrefrontal cortex transcriptomes distinguish Alzheimer’s disease from asymptomatic amyloid pathology, neuropeptide loss, immune-complement activation and glial remodellingbiorxiv-preprint · 2026 · n=15 · 341 differentially expressed genes (DEGs) in AD versus Normal, n=8, adjusted P < 0.05.HumanBSex differences in cell type-specific transcriptional programs and GPCR signaling in the human subgenual anterior cingulate cortexbiorxiv-preprint · 2026 · n=19 · Not reported in abstract.HumanDHeterogeneity of microbiome responses to menopausal hormone therapy among perimenopausal women.Nature medicine · 2026—CLongitudinal Imaging in a Mouse Model of Focal Cortical Dysplasia Reveals Lesion Expansion and Loss of Pre-Discharge Neuronal Recruitmentbiorxiv-preprint · 2026 · Not reported in abstract.AnimalCCortex-wide imaging in naturally behaving mice with 1-gram wireless mesoscopes.Nature · 2026Animal